
    
      Participants will be managed in an outpatient setting. Hematologic function, liver enzymes,
      renal function and electrolytes will be monitored. Blood for immune function analyses
      including IFNÎ³-ELISPOT analysis of cytotoxic T cell activation in response to autologous
      tumor antigens will be collected at tissue procurement, post-procurement screening and Day 1
      (prior to chemotherapy administration) at Cycles 2, 4, and 6, end of treatment (EOT), 3
      months after EOT, and every 6 months thereafter. Blood for ctDNA analysis will be collected
      at tissue procurement, prior to chemotherapy administration at baseline and on Day 1 prior to
      chemotherapy administration at Cycles 2, 3, 4, and 6, and EOT.
    
  